Vertex Pharmaceuticals Inc. Stock

What if you only had $1,000 to invest in stocks and had to put the money to work today? Which stocks would you buy? That's admittedly not an easy question to answer. I can think of lots of stocks

You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk. The good news, though, is that

The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more

Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while

Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to the

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday

Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) first-quarter financial report.

Vertex's first-quarter financial results didn't keep up with what investors have gotten used to

Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about

Is a recession coming? Our economic outlook seems increasingly gloomy due to President Trump's trade policies. Though things might not go that far, it's still worth planning ahead.

If a recession

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility.

However, three Fool.com

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their hard-earned money into specific companies based on their preferences, risk

Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging populations, the demand for healthcare products and services should grow

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.

However, I remain

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And

Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report.

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings

Image source: The Motley Fool.

Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2024 Earnings CallFeb 10, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Vertex Pharmaceuticals(NASDAQ:VRTX), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was